The phrase "a promising phase" is correct and usable in written English.
It can be used to describe a period or stage that shows potential for positive outcomes or developments.
Example: "The company is entering a promising phase of growth, with new projects and partnerships on the horizon."
Alternatives: "a hopeful stage" or "an encouraging period".
But with Ariad's stock trading under $6.00 (total cash on hand per share is $1.43) the company's shares are trading mostly on optimism about its most advanced drug, a promising phase II cancer agent called AP23573.
Nikki Walker had the home crowd on their feet after a fourth-minute line-break but a promising phase broke down under the posts due to an overly-ambitious pass from Ruaridh Jackson.
Unfortunately, despite a promising Phase 1 clinical trial, these results were not borne out by the Phase 2 study.
This might occur when a clinical team wants to quickly transition from a promising phase II study that used a CTA to a pivotal phase III study before the companion diagnostic is in its final form.
In this respect, this study could be considered analogous to a very promising phase II study of a potential new drug, meriting a subsequent phase III follow-up study.
These two different treatment modalities have been studied in a number of promising phase II trials but there are very limited data from positive randomised phase III trials (Schaake-Koning et al, 1994; Furuse et al, 1999).
It is envisaged the use of MBGZ-7 as a promising dispersed phase in composite materials for minimally invasive surgery procedures, such as injectable bone cements, in order to allow the visualization of the implant under fluoroscopic control, during both injection and follow-up.
Complimenting Cudi's "introspective persona, ear for melody, and eclectic taste in beats," Entertainment Weekly music reviewer Simon Vozick-Levinson called him "a hyped upstart who really does represent a promising new phase in the genre's evolution".
On the basis of these promising phase I data, we are now conducting a phase II study of bevacizumab with this intermittent schedule of sorafenib in EOC.
There are also some promising phase II data using docetaxel which gave a 23% RR in a group of 22 patients when given at a dose of 100 mg m−2 (Vorobiof et al, 2000).
At this year's American Association for Cancer Research AACRR) Annual Meeting, Agios Pharmaceuticals announced very promising phase I clinical data from AG-221, an oral drug that is a selective, potent inhibitor of the mutated form of IDH2.
